Public Employees Retirement Association of Colorado lessened its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 4.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,167 shares of the biopharmaceutical company’s stock after selling 1,950 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Alexion Pharmaceuticals were worth $5,775,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ALXN. BlackRock Inc. grew its stake in shares of Alexion Pharmaceuticals by 7.0% during the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after buying an additional 1,298,185 shares during the last quarter. Third Point LLC bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $152,088,000. Bank of Montreal Can grew its stake in shares of Alexion Pharmaceuticals by 628.8% during the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock worth $173,174,000 after buying an additional 1,228,025 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Alexion Pharmaceuticals by 1,697.6% during the second quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock worth $139,424,000 after buying an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Alexion Pharmaceuticals by 42.2% during the second quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock worth $391,773,000 after buying an additional 955,578 shares during the last quarter. 94.55% of the stock is currently owned by hedge funds and other institutional investors.

ALXN has been the topic of a number of research reports. Royal Bank Of Canada boosted their target price on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 14th. BidaskClub cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Deutsche Bank AG reissued a “buy” rating and issued a $158.00 price objective (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $154.01.

In other news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the sale, the executive vice president now directly owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,490 shares of company stock valued at $2,337,251. 4.35% of the stock is currently owned by insiders.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $117.95 on Friday. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The company has a market cap of $26,351.21, a PE ratio of 24.12, a PEG ratio of 1.29 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 earnings per share. research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Public Employees Retirement Association of Colorado Decreases Holdings in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/public-employees-retirement-association-of-colorado-decreases-holdings-in-alexion-pharmaceuticals-inc-alxn/1680649.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.